ClinicaliQ Trial Snapshot
- Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia — Recruiting • Phase III • Mental Health / Psychiatry • NCT07686263.
- KarXT may help prevent relapse in schizophrenia patients already responding to treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia Conditions: Schizophrenia Interventions: Xanomeline/Trospium Chloride, Placebo Lead Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company Planned Enrollment: 472 participants